Objective: The usefulness of bevacizumab (BEV) as first-line chemotherapy for advanced ovarian clear cell carcinoma (CCC) was retrospectively evaluated at Tohoku Gynecologic Cancer Unit institutions.Patients and Methods: A total of 81 patients (52 patients without BEV and 29 with BEV) with advanced ovarian CCC who received initial platinum-based chemotherapy were enrolled. We selected 26 patients each without and with BEV according to propensity score matching methods, and compared the platinum-resistant recurrence rate, response rate, progression-free survival (PFS), overall survival (OS), and adverse events between the two groups.Results: The objective response rates for the patients with measurable disease in the non-BEV and BEV groups were 60.0% and 95.5%, respectively (p= 0.007). The recurrence of platinum-resistant patients was observed in 50.0% of the non-BEV group and 23.1% of the BEV group (p= 0.117). The median PFS was 12 and 22 months, respectively (p= 0.034), and the median OS was 32 and 47 months, respectively (p= 0.223). In the BEV group, grade 3 hypertension and proteinuria occurred in two patients, and thrombosis and carboplatin hypersensitivity occurred in one patient. Grade 4 gastrointestinal perforation occurred in one patient.Conclusions: First-line chemotherapy with BEV in advanced CCC showed the potential for high response rates and improved PFS.
目的：本研究回顾性评估了东北妇科癌症协作组机构中贝伐珠单抗（BEV）作为晚期卵巢透明细胞癌（CCC）一线化疗方案的有效性。 患者与方法：共纳入81例接受初始铂类化疗的晚期卵巢CCC患者（52例未使用BEV，29例使用BEV）。通过倾向评分匹配法，我们分别选取了26例未使用BEV和26例使用BEV的患者，比较两组间的铂耐药复发率、缓解率、无进展生存期（PFS）、总生存期（OS）及不良事件。 结果：在可测量病灶患者中，非BEV组与BEV组的客观缓解率分别为60.0%和95.5%（p=0.007）。铂耐药复发率在非BEV组为50.0%，BEV组为23.1%（p=0.117）。中位PFS分别为12个月和22个月（p=0.034），中位OS分别为32个月和47个月（p=0.223）。BEV组中，2例患者出现3级高血压和蛋白尿，1例出现血栓及卡铂过敏反应，1例发生4级胃肠道穿孔。 结论：贝伐珠单抗作为晚期卵巢透明细胞癌的一线化疗方案，展现出提高缓解率和改善无进展生存期的潜力。
肿瘤(癌症)患者之家